LXEO (Lexeo Therapeutics) Buyback Yield % : -84.55 (As of Apr. 22, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Lexeo Therapeutics's current buyback yield was -84.55%.

Lexeo Therapeutics Buyback Yield % Historical Data

The historical data trend for Lexeo Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Buyback Yield % Chart

Lexeo Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

-28.04

-40.75

Lexeo Therapeutics Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial								-28.04	-17.19	-16.74	-29.68	-40.75

Competitive Comparison of Lexeo Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Lexeo Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexeo Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Lexeo Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Lexeo Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-0.017	+	88.712)	/	217.6335
	=	-40.75%

Lexeo Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (-0.017	+	88.712)		/	217.6335
	=	-40.75%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Lexeo Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Lexeo Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexeo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Park Avenue South, Floor 6, New York, NY, USA, 10010

Website

https://www.lexeotx.com

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Executives

Richard Nolan Townsend	director, officer: Chief Executive Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson	officer: Chief Legal and Admin. Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler	officer: Chief Scientific Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paula H Cholmondeley	director	221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Paul Mccormac	officer: Chief Technical Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian	director	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Reinaldo M Diaz	director	C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830